Status:
RECRUITING
DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer
Lead Sponsor:
University of Alabama at Birmingham
Conditions:
Borderline-resectable Pancreatic Cancer
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
The goal of this study is to test whether chemotherapy guided by a new imaging method named DCE-MRI can more effectively reduce a pancreatic tumor, enabling curable surgery, over the conventional meth...
Eligibility Criteria
Inclusion
- Adult patients (age 19 years or older).
- Patients with newly diagnosed and untreated borderline resectable pancreatic cancer.
- Patients with signed informed consent.
Exclusion
- Any history of prior radiation or chemotherapy or surgical removal for pancreatic cancer.
- Participants with safety contraindications to MRI examination (determined by standard clinical screening).
- Participants who are pregnant, lactating or are planning to become pregnant during the study.
- Participants who are planning to father a child during the study.
Key Trial Info
Start Date :
October 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2029
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06173310
Start Date
October 10 2024
End Date
March 1 2029
Last Update
February 17 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
Indiana University Medical Center
Indianapolis, Indiana, United States, 46202